{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000036","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.306523+00:00","generated_at":"2026-06-24T18:07:28.034836+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks","bullets":["Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.","Total cost capped at ~$2.2M; initial payment ~$0.2M; payments in Chinese yuan.","Related party: CEO Jack Zhang & Chairman Mary Luo family own majority of Hanxin; approved by independent Audit Committee.","Agreement term three years; Amphastar owns all title to RCBs and related IP."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000036","json":"https://secwatch.observer/filing/0001297184-22-000036.json","markdown":"https://secwatch.observer/filing/0001297184-22-000036.md","text":"https://secwatch.observer/filing/0001297184-22-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/0001297184-22-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/amph-20220705x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T18:07:28.034836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}